Samrat Pharmachem Limited (SAMRATPH.BO) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+110.6%

₹567.31

vs ₹269.40 price

Levered DCF

₹209.87

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

—

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-18.19×	14.17×	53.4×	6.89×	8.72×	8.11×	4.37×	15.35×
P/B	0.88×	1.4×	1.78×	1.82×	3.2×	1.46×	0.76×	1.17×
P/S	0.21×	0.35×	0.41×	0.37×	0.68×	0.24×	0.13×	0.21×
EV / EBITDA	-49.74×	9.86×	29.65×	4.97×	5.74×	5.54×	4.06×	8.83×
Gross margin	1.3%	5.3%	4.0%	9.3%	12.7%	6.6%	6.9%	5.7%
Operating margin	-1.0%	3.4%	0.8%	7.6%	10.7%	7.3%	4.5%	2.5%
Net margin	-1.1%	2.5%	0.8%	5.4%	7.7%	3.0%	3.1%	1.4%
Current ratio	1.86×	2.08×	1.82×	1.85×	1.91×	1.73×	1.47×	1.69×
Debt / equity	0.16×	0.14×	0.13×	0.3×	0.16×	0.3×	0.39×	0.33×
Interest coverage	-2.99×	14.22×	3.16×	19.12×	35.28×	10.27×	6.3×	2.59×
Dividend yield	0.5%	0.3%	0.3%	0.3%	0.0%	0.0%	0.0%	0.0%
Payout ratio	-9.3%	4.3%	14.3%	1.9%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-4.9%	9.9%	3.3%	26.3%	36.7%	18.0%	17.4%	7.7%
Return on invested capital	-3.6%	8.4%	2.5%	21.3%	31.6%	24.5%	13.3%	7.2%
Return on assets	-2.7%	5.9%	1.8%	14.3%	20.3%	9.3%	7.3%	3.8%
Free cash flow yield	8.5%	-10.8%	7.6%	-9.4%	10.8%	4.8%	-17.1%	8.8%
Earnings yield	-5.5%	7.1%	1.9%	14.5%	11.5%	12.3%	22.9%	6.5%
Enterprise value	₹649.5M	₹1.1B	₹1.1B	₹1.2B	₹1.4B	₹495.1M	₹267.4M	₹278.6M
Net debt / EBITDA	-3.61×	0.87×	-0.31×	0.28×	-0.29×	0.7×	1.25×	1.36×
Cash conversion cycle (days)	65	71	53	62	51	54	63	54